person · Reporting owner

RIEDEL NORBERT G

Disclosed activity across 5 companies

Tapewire entity: 903
SEC CIK: 0001161662

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aptinyx Inc.APTX · Entity 120922	Director · EXECUTIVE CHAIRMAN OF THE BOD	January 03, 2023	January 05, 2023
Eton Pharmaceuticals, Inc.ETON · Entity 4598	Director	July 31, 2026	August 04, 2026
Jazz Pharmaceuticals plcJAZZ · Entity 818	Director	August 31, 2026	September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aptinyx Inc.

Report date January 03, 2023 · Filed January 05, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2033-01-02	Direct	420,000	Reported balance After 2023-01-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-03 · Grant · Acquired 420,000 · Balance 420,000 F1: This option shall vest 25% on January 3, 2024, with the remaining 75% vesting in equal monthly installments over 36 months.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest 25% on January 3, 2024, with the remaining 75% vesting in equal monthly installments over 36 months.

Eton Pharmaceuticals, Inc.

Report date July 31, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table II · derivative / convertible security	Direct	10,000	Reported balance After 2026-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-31 · Grant · Acquired 10,000 · Balance 10,000 F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

Filing footnotes · ownership attribution and instrument terms

F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.

Jazz Pharmaceuticals plc

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	6,923	Ending reported balance After 2026-08-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 8,615 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 6,923 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Ordinary SharesSEC Table I · non-derivative	Indirectby Trust	10,630	Reported balance Holding disclosure · report date 2026-08-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 10,630

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARIAD PHARMACEUTICALS INC

Report date February 16, 2017 · Filed February 16, 2017

Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-02-16 transaction · row 1 1 source row Row 1 · 2017-02-16 · Disposition to issuer · Disposed 139,867 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.50	Direct	Reported balance After 2017-02-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39	Direct	Reported balance After 2017-02-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45	Direct	Reported balance After 2017-02-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.91	Direct	Reported balance After 2017-02-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82	Direct	Reported balance After 2017-02-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.

F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.

F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

Cerevel Therapeutics Holdings, Inc.

Report date August 01, 2024 · Filed August 05, 2024

Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-08-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-08-01 · Disposition to issuer · Disposed 46,092 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-08-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-01 · Disposition to issuer · Disposed 95,242 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.

F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2021 Filed Jun 15, 2021 00:14 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	58,003	$0.00 Strike: $13.93	$0.00	Disclosure SEC source: 0000899243-21-023723 · doc4.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,003 Underlying: Common Stock · 58,003 shares Expires 2031-06-10 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
May 17, 2021 Filed May 19, 2021 22:46 UTC	Aptinyx Inc. APTX · Entity 120922	Exercise / conversionRestricted Stock Units · Derivative	380,000	$0.00	$0.00	Disclosure SEC source: 0001415889-21-002573 · form4-05192021_030509.xml · derivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 380,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. The underlying vested shares settled on May 17, 2021, the business day immediately following May 16, 2021. F4 · derivative.expiration_date: The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. The underlying vested shares settled on May 17, 2021, the business day immediately following May 16, 2021. Read SEC document
May 17, 2021 Filed May 19, 2021 22:46 UTC	Aptinyx Inc. APTX · Entity 120922	Tax withholdingCommon Stock	127,274	$2.53	$322,003.22	Disclosure SEC source: 0001415889-21-002573 · form4-05192021_030509.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,265 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document
May 17, 2021 Filed May 19, 2021 22:46 UTC	Aptinyx Inc. APTX · Entity 120922	Exercise / conversionCommon Stock	380,000	$0.00	$0.00	Disclosure SEC source: 0001415889-21-002573 · form4-05192021_030509.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock issued to the reporting person upon settlement of the RSUs on May 17, 2021, the business day immediately following May 16, 2021, the date that the RSUs became fully vested. Read SEC document
May 17, 2021 Filed May 20, 2021 21:53 UTC Amendment	Aptinyx Inc. APTX · Entity 120922	Exercise / conversionRestricted Stock Units · Derivative	380,000	$0.00	$0.00	Disclosure SEC source: 0001415889-21-002619 · form4a-05202021_020551.xml · derivative · entry 6 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 380,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. The underlying vested shares settled on May 17, 2021, the business day immediately following May 16, 2021. F4 · derivative.expiration_date: The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. The underlying vested shares settled on May 17, 2021, the business day immediately following May 16, 2021. Read SEC document
May 17, 2021 Filed May 20, 2021 21:53 UTC Amendment	Aptinyx Inc. APTX · Entity 120922	Tax withholdingCommon Stock	127,274	$2.53	$322,003.22	Disclosure SEC source: 0001415889-21-002619 · form4a-05202021_020551.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,265 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document
May 17, 2021 Filed May 20, 2021 21:53 UTC Amendment	Aptinyx Inc. APTX · Entity 120922	Exercise / conversionCommon Stock	380,000	$0.00	$0.00	Disclosure SEC source: 0001415889-21-002619 · form4a-05202021_020551.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Common Stock issued to the reporting person upon settlement of the RSUs on May 17, 2021, the business day immediately following May 16, 2021, the date that the RSUs became fully vested. Read SEC document
May 03, 2021 Filed May 5, 2021 20:15 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantStock Option (Right to buy) · Derivative	19,655	$0.00 Strike: $8.61	$0.00	Disclosure SEC source: 0001493152-21-010525 · ownership.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,555 Underlying: Common Stock · 19,655 shares Expires 2031-05-03 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022. Read SEC document
February 24, 2021 Filed Feb 27, 2021 00:34 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	733,300	$0.00 Strike: $3.80	$0.00	Disclosure SEC source: 0001415889-21-001006 · form4-02262021_040246.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,300 Underlying: Common Stock · 733,300 shares Expires 2031-02-23 F1 · derivative.exercise_date: This option shall vest 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments over 36 months. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:26 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionRestricted Stock Units · Derivative	14,270	$0.00	$0.00	Disclosure SEC source: 0000899243-21-000688 · doc4.xml · derivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,270 Underlying: Common Stock · 14,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 14,270 RSUs vested on January 4, 2021, the second anniversary of the vesting commencement date of January 4, 2019 (the "Vesting Commencement Date"), with the remainder vesting on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service relationship with the Issuer through each such date. F2 · derivative.expiration_date: 14,270 RSUs vested on January 4, 2021, the second anniversary of the vesting commencement date of January 4, 2019 (the "Vesting Commencement Date"), with the remainder vesting on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service relationship with the Issuer through each such date. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:26 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionCommon Stock	14,270	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-000688 · doc4.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. Read SEC document
August 07, 2020 Filed Aug 10, 2020 20:50 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	931	$125.87	$117,185.71	Disclosure SEC source: 0001765581-20-000079 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,459 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 06, 2020 Filed Aug 10, 2020 20:50 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	6,765	$0.00 Strike: $127.07	$0.00	Disclosure SEC source: 0001765581-20-000079 · edgardoc.xml · derivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Underlying: Ordinary Shares · 6,765 shares Expires 2030-08-05 F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021. Read SEC document
August 06, 2020 Filed Aug 10, 2020 20:50 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	2,705	$0.00	$0.00	Disclosure SEC source: 0001765581-20-000079 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,390 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021. Read SEC document
March 12, 2020 Filed Mar 16, 2020 20:52 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantStock Option (Right to buy) · Derivative	27,400	$0.00 Strike: $3.58	$0.00	Disclosure SEC source: 0001493152-20-004053 · ownership.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Underlying: Common Stock · 27,400 shares Expires 2030-03-11 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021. Read SEC document
February 26, 2020 Filed Feb 28, 2020 21:34 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	625,000	$0.00 Strike: $3.12	$0.00	Disclosure SEC source: 0001567619-20-005135 · doc1.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Commmon Stock · 625,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: This option shall vest 25% on February 26, 2021, with the remaining 75% vesting in equal monthly installments over 36 months. Read SEC document
January 10, 2020 Filed Jan 14, 2020 21:23 UTC	Aptinyx Inc. APTX · Entity 120922	PurchaseCommon Stock	35,000	$3.00	$105,000.00	Disclosure SEC source: 0001567619-20-001019 · doc1.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · by Norbert G. Riedel 2015 Family Trust Disclosed balance after: 35,000 Read SEC document
August 09, 2019 Filed Aug 12, 2019 21:32 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	726	$135.65	$98,481.68	Disclosure SEC source: 0001765581-19-000074 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,685 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.60 to $135.65. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
August 08, 2019 Filed Aug 12, 2019 21:32 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	4,805	$0.00 Strike: $137.12	$0.00	Disclosure SEC source: 0001765581-19-000074 · edgardoc.xml · derivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Ordinary Shares · 4,805 shares Expires 2029-08-07 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. Read SEC document
August 08, 2019 Filed Aug 12, 2019 21:32 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,920	$0.00	$0.00	Disclosure SEC source: 0001765581-19-000074 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,411 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020. Read SEC document
May 16, 2019 Filed May 17, 2019 23:01 UTC	Aptinyx Inc. APTX · Entity 120922	GrantRestricted Stock Units · Derivative	380,000	$0.00	$0.00	Disclosure SEC source: 0001104659-19-030348 · a4.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Stock · 380,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. F2 · derivative.expiration_date: The restricted stock units vest on May 16, 2021, subject to the Reporting Person's continued service. Read SEC document
February 20, 2019 Filed Mar 8, 2019 21:35 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	GrantStock option (right to buy) · Derivative	12,500	$0.00 Strike: $7.31	$0.00	Disclosure SEC source: 0001209191-19-018122 · doc4.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-02-19 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20, 2020. Read SEC document
January 04, 2019 Filed Jan 7, 2019 21:26 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	275,000	$0.00 Strike: $19.33	$0.00	Disclosure SEC source: 0001104659-19-001129 · a4.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: This option shall vest 25% on January 4, 2020, with the remaining 75% vesting in equal monthly installments over 36 months. Read SEC document
November 15, 2018 Filed Nov 16, 2018 00:10 UTC	Eton Pharmaceuticals, Inc. ETON · Entity 4598	PurchaseCommon Stock	5,000	$6.00	$30,000.00	Disclosure SEC source: 0001209191-18-058824 · doc4.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,745 Read SEC document
November 12, 2018 Filed Nov 14, 2018 21:16 UTC	Aptinyx Inc. APTX · Entity 120922	Exercise / conversionStock Option (Right to Buy) · Derivative	38,563	$0.00 Strike: $2.59	$0.00	Disclosure SEC source: 0001104659-18-068453 · a4.xml · derivative · entry 4 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,615 Underlying: Common Stock · 38,563 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest 25% on January 19, 2018 and the remaining 75% shall vest in equal monthly installments over 36 months. Read SEC document
November 12, 2018 Filed Nov 14, 2018 21:16 UTC	Aptinyx Inc. APTX · Entity 120922	Exercise / conversionCommon Stock	38,563	$2.59	$99,878.17	Disclosure SEC source: 0001104659-18-068453 · a4.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 20, 2018 Filed Sep 21, 2018 20:17 UTC	Aptinyx Inc. APTX · Entity 120922	GrantStock Option (Right to Buy) · Derivative	427,265	$0.00 Strike: $27.43	$0.00	Disclosure SEC source: 0001104659-18-058017 · a4.xml · derivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,265 Underlying: Common Stock · 427,265 shares Expires 2028-09-19 F1 · derivative.exercise_date: This option shall vest 25% on September 20, 2019, with the remaining 75% vesting in equal monthly installments over 36 months. Read SEC document
August 10, 2018 Filed Aug 13, 2018 23:57 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	660	$176.61	$116,563.06	Disclosure SEC source: 0001232524-18-000160 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,491 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.61 to $177.052. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
August 09, 2018 Filed Aug 13, 2018 23:57 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,735	$0.00 Strike: $177.73	$0.00	Disclosure SEC source: 0001232524-18-000160 · edgardoc.xml · derivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,735 Underlying: Ordinary Shares · 3,735 shares Expires 2028-08-08 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. Read SEC document
August 09, 2018 Filed Aug 13, 2018 23:57 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,495	$0.00	$0.00	Disclosure SEC source: 0001232524-18-000160 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,151 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries B Convertible Preferred Stock · Derivative	836,541	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042295 · a4.xml · derivative · entry 10 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,324 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries A-2 Convertible Preferred Stock · Derivative	1,334,254	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042295 · a4.xml · derivative · entry 9 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries A-1 Convertible Preferred Stock · Derivative	75,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042295 · a4.xml · derivative · entry 8 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · By family members Disclosed balance after: 0 Underlying: Common Stock · 2,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionSeries A-1 Convertible Preferred Stock · Derivative	1,042,482	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042295 · a4.xml · derivative · entry 7 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	PurchaseCommon Stock	2,400	$16.00	$38,400.00	Disclosure SEC source: 0001104659-18-042295 · a4.xml · nonDerivative · entry 5 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · By family members Disclosed balance after: 5,118 F2 · shares: On June 25, 2018, certain family members of the Reporting Person collectively purchased 2,400 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	2,718	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042295 · a4.xml · nonDerivative · entry 4 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · By family members Disclosed balance after: 2,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	30,324	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042295 · a4.xml · nonDerivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	48,367	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042295 · a4.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. Read SEC document
June 25, 2018 Filed Jun 26, 2018 20:44 UTC	Aptinyx Inc. APTX · Entity 120922	ConversionCommon Stock	37,790	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-042295 · a4.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F1 · price: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. Read SEC document
August 11, 2017 Filed Aug 14, 2017 21:27 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3	$144.13	$432.39	Disclosure SEC source: 0001232524-17-000148 · edgardoc.xml · nonDerivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,656 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 11, 2017 Filed Aug 14, 2017 21:27 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	659	$142.36	$93,815.24	Disclosure SEC source: 0001232524-17-000148 · edgardoc.xml · nonDerivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,659 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 10, 2017 Filed Aug 14, 2017 21:27 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,415	$0.00 Strike: $143.66	$0.00	Disclosure SEC source: 0001232524-17-000148 · edgardoc.xml · derivative · entry 4 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,415 Underlying: Ordinary Shares · 3,415 shares Expires 2027-08-09 F3 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. Read SEC document
August 10, 2017 Filed Aug 14, 2017 21:27 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,365	$0.00	$0.00	Disclosure SEC source: 0001232524-17-000148 · edgardoc.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,318 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. F1 · shares: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:16 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $23.82	$0.00	Disclosure SEC source: 0000884731-17-000053 · wf-form4_148727255357743.xml · derivative · entry 6 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:16 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $4.91	$0.00	Disclosure SEC source: 0000884731-17-000053 · wf-form4_148727255357743.xml · derivative · entry 5 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:16 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $6.45	$0.00	Disclosure SEC source: 0000884731-17-000053 · wf-form4_148727255357743.xml · derivative · entry 4 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:16 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $7.39	$0.00	Disclosure SEC source: 0000884731-17-000053 · wf-form4_148727255357743.xml · derivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:16 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $8.50	$0.00	Disclosure SEC source: 0000884731-17-000053 · wf-form4_148727255357743.xml · derivative · entry 2 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:16 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerCommon Stock	139,867	Not disclosed	Not disclosed	Disclosure SEC source: 0000884731-17-000053 · wf-form4_148727255357743.xml · nonDerivative · entry 1 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2 · price: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
January 31, 2017 Filed Feb 1, 2017 16:55 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GrantEmployee Stock Option (Right to Buy) · Derivative	25,000	$23.82 Strike: $23.82	$595,500.00	Disclosure SEC source: 0000884731-17-000011 · wf-form4_148598610444217.xml · derivative · entry 3 RIEDEL NORBERT G · CIK 0001161662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-31 F3 · derivative.exercise_date: The stock options granted under our 2014 Long-Term Incentive Plan, as amended, and in accordance with our director compensation policy vest as to approximately one-fourth of the shares underlying the options on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.